Certuma raises $10M to build the first FDA-approved AI doctor
What's the deal? Serial entrepreneur Martin VarsavskyDealroom has a profile for this one. Try Dealroom → has launched Certuma, an Austin, Texas-based startup that aims to build the first AI doctor with formal approval from the US Food and Drug AdministrationDealroom has a profile for this one. Try Dealroom →.
The company has raised $10M in seed funding, led by Joe LonsdaleDealroom has a profile for this one. Try Dealroom →'s 8VC, at a $60M valuation. Certuma's goal is to build a system that can diagnose, prescribe treatments, and order tests autonomously — going well beyond today's AI tools, which stop short of medical decisions.
The problem it targets is structural. Over 100 million Americans face barriers to primary care, 46% of US counties lack a cardiologist, and the shortage is worsening. Certuma plans to start with 25 low-risk, high-frequency conditions — urinary tract infections, strep throat, sinusitis — where clinical decision trees are well-defined.
Why now? AI tools have reached a level of clinical competence that makes autonomous medical decision-making plausible for the first time. Meanwhile, a deepening physician shortage, especially in rural areas, is increasing pressure to find structural alternatives to traditional care delivery.
What could go wrong? Seemingly simple cases can mask serious diagnoses — a sore throat could be laryngeal cancer, a headache could signal meningitis. Robert WachterDealroom has a profile for this one. Try Dealroom →, head of medicine at the University of California San FranciscoDealroom has a profile for this one. Try Dealroom →, warns that the system must be trained to catch those exceptions.
AI hallucinations are another risk: confident but incorrect outputs can be dangerous in clinical settings. Certuma is building a separate deterministic safety layer — rule-based, not generative — to flag anomalies and escalate to a human physician.
The regulatory path is equally treacherous. The FDA has never approved a multi-condition autonomous diagnostic system. Certuma's most likely route is a condition-by-condition approval process — starting with urinary tract infections — which would be slow and costly. Varsavsky estimates the full regulatory journey could cost hundreds of millions of dollars.
The signal: Certuma reflects a broader shift in AI health ambitions — from decision-support copilots to autonomous medical infrastructure. If it succeeds, it could set a regulatory template for AI doctors globally. The startup is also running clinical trials in Argentina, where costs are lower, pointing to an increasingly multinational approach to building and validating AI health tools.
Sources:
Forbes
El Observador
Martin Varsavsky's LinkedIn post
Image credit:
Certuma
J.V.
